Orchestra BioMed Holdings, Inc./$OBIO

1D1W1MYTD1Y5YMAX

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Ticker
$OBIO
Sector
Health
Primary listing
NASDAQ
Employees
86
Headquarters
New Hope, United States
Website
www.orchestrabiomed.com

OBIO Metrics

BasicAdvanced
$358M
-
-$1.00
0.50
-

Bulls say / Bears say

AVIM has produced encouraging pilot data, with an 8.1 mmHg net reduction in 24-hour ambulatory systolic blood pressure at six months versus control. The programme also has two FDA Breakthrough Device Designations and is approaching completion of its pivotal trial. (GlobeNewswire, GlobeNewswire)
Orchestra has strong strategic backing from Medtronic, Terumo and Ligand, while Medtronic is positioned to handle regulatory, manufacturing and sales for AVIM. This gives Orchestra access to an established commercial platform and reduces the need to build its own sales organisation. (StockAnalysis, BioSpace)
Virtue SAB offers a differentiated approach by delivering liquid sirolimus from a non-coated balloon, and it is being tested directly against the established AGENT product. Its Breakthrough Device status and ongoing enrolment create a second potential value driver beyond AVIM. (StockAnalysis, GlobeNewswire)
AVIM remains an investigational therapy, so the investment case still depends on a binary BACKBEAT result. Enrollment is targeted for the end of Q3 2026, but primary data is not expected until Q2 2027 and regulatory submission is conditional on meeting the safety and efficacy endpoints. (GlobeNewswire)
Virtue SAB is at an earlier stage than AVIM and its pivotal trial is still ramping up. It must first show at least non-inferiority against Boston Scientific’s AGENT balloon, while any hoped-for superiority remains an additional hurdle. (StockAnalysis, BioSpace)
The company has negligible commercial revenue, continues to post substantial losses and expects to need more capital as development continues. Its funding includes debt and royalty obligations, so delays could increase financing needs and dilution risk before either product reaches the market. (StockTitan, CapEdge)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.

Funds containing OBIO

AllUSDGBP
Funds
Fund name
Fund size
$OBIO weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.03%
iShares Nasdaq US Biotechnology£BTEK
£865M0.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.